drugset / Trial / NCT04618497

A Pilot Study on the Use of Methoxyflurane (Penthrox®) for Pain Control in the Emergency Department

NCT04618497

Phase 3 Completed 40 enrolled Hospital Authority, Hong Kong
RandomizedParallel-groupOpen-labelTreatment

Summary

Patients commonly visit the emergency department (ED) for pain after musculoskeletal injury and need early treatment with analgesic. Prompt and adequate pain relief can reduce suffering and promote early discharge and return to work. Nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids are the major injectable analgesic used for moderate to severe pain in EDs in Hong Kong. They are given via intravenous or intramuscular route for faster onset of action to achieve rapid pain relief in the emergency setting. However, injections are invasive and can be distressing for patients. Methoxyflurane (Penthrox®) is recently introduced to our emergency department as an inhalational analgesic. It has been granted registration approval in Hong Kong since 2018, but it is not widely used in the locality. Methoxyflurane is a volatile fluorinated hydrocarbon self-administrated by inhalation through a portable hand-held whistle-shaped inhaler device (Penthrox®) to relieve pain associated with trauma or minor surgical procedures in stable and conscious patients. In this study, the investigators will evaluate the efficacy and safety Penthrox® in the treatment of acute traumatic pain in hospital emergency department setting by comparing it to another conventional analgesic commonly used.

Timeline

Start
2020-10-28
Primary completion
2020-11-21
Completion
2020-11-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketorolac Other / unclassified 30 mg Intramuscular
Subject Methoxyflurane Small molecule 3 ml Inhaled

Indications

No indication recorded.